All In Biotech

Drug Trial Radar · NCT07854197

Effect of Remimazolam on Hypoxemia and/or Hypotension in Prostate Biopsy

Effect of Remimazolam Sedation on Composite Adverse Events in Elderly Patients Undergoing Prostate Biopsy: A Prospective Multicenter Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 1,146 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,146

Planned (sponsor's estimate)

Start

Oct 8, 2026

Primary completion

Jun 30, 2027

Study completion Jul 1, 2027

Sponsor

Lead sponsor
RenJi HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Other
FDA-regulated drug
No
Who can join
Male only, from 65 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to investigate whether remimazolam, a novel benzodiazepine sedative, can reduce the composite incidence of hypotension and hypoxemia during prostate biopsy in elderly patients compared with propofol. This study is a multicenter prospective randomized controlled trial.Participants will be recruited from five centers: Renji Hospital (Shanghai), Sun Yat-sen University Cancer Center, Zhongda Hospital (Nanjing), Shenzhen Hospital of the Cancer Hospital (CAMS), and Liaoning Fangda General Hospital.Baseline data will be collected for all participants, including demographic information, comorbidities, concurrent medication use, and vital signs.A total of 1,146 eligible participants will be randomized in a 1:1 ratio to receive either remimazolam (experimental group) or propofol (control group). Intraoperative hypoxemia and hypotension will be recorded as the primary outcomes. Secondary outcomes will include other sedation-related adverse events and patient satisfaction, which will be evaluated to comprehensively assess the efficacy and safety profile of remimazolam.

Conditions

  • Prostate Biopsy
  • Sedation Complication

Interventions

  • Using remimazolam for sedation during prostate biopsyDrug

    Administer 0.2mg/kg remimazolam, with the infusion time exceeding 10 seconds. Once the subject reaches a sufficient level of sedation (MOAA/S score ≤ 1), the operating doctor performs local infiltration anesthesia at the perineal puncture site with 5-10ml of 2% lidocaine, and then begins the prostate puncture procedure.

  • Administer 1.5mg/kg of propofol for sedationDrug

    Administer 1.5mg/kg of propofol, with the injection time exceeding 10 seconds. Once the subject reaches a sufficient level of sedation (MOAA/S score ≤ 1), the operating doctor performs local infiltration anesthesia at the perineal puncture site with 2% lidocaine, and then begins the prostate puncture procedure.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of composite adverse events during sedationTime frame: During the sedation period of the prostate biopsy procedure

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.